| Characteristics | All (N = 70) | |
| No. | % | |
| Age (years) |
| |
| Mean ± SD | 50.24 ± 9.58 | |
| Median (Range) | 52.50 (27 - 62) | |
| Grade |
|
|
| Low | 18 | 27.7% |
| High | 52 | 74.3% |
| LN |
|
|
| Negative | 22 | 31.4% |
| Positive | 48 | 68.6% |
| Stage |
|
|
| Stage I | 8 | 11.4% |
| Stage II | 12 | 17.1% |
| Stage III | 32 | 45.7% |
| Stage IV | 18 | 25.7% |
| CA125 (u/ml) |
| |
| Mean ± SD | 1071.31 ± 666.91 | |
| Median (Range) | 1238.50 (69 - 2008) | |
| Gal-1 (ng/ml) |
| |
| Mean ± SD | 334.84 ± 187.67 | |
| Median (Range) | 277 (32 - 763) | |
| Gal-1 |
|
|
| Weak | 22 | 31.4% |
| Strong | 48 | 68.6% |
| Gal-1 tumor cells |
|
|
| Weak | 24 | 34.3% |
| Strong | 46 | 65.7% |
| Follow-up duration (months) |
| |
| Mean ± SD | 15.45 ± 8.45 | |
| Median (Range) | 14 (3 - 36) | |
| Outcome |
|
|
| Alive | 54 | 77.1% |
| Died | 16 | 22.9% |